Generic Semaglutide Set to Hit Market

The active ingredient, semaglutide, is the focus of a complex global patent landscape. While key patents for the drug are held by Novo Nordisk until around 2032 in the United States, they are set to expire in other major markets, including China, in 2026. This staggered patent expiration means that generic versions of semaglutide are anticipated to launch internationally years before they become available in the U.S. This global-first approach is becoming more common in the pharmaceutical industry. The price disparity for the brand-name versions, Ozempic and Wegovy, is already significant. In the U.S., the list price for a month's supply of Ozempic is $936, and for Wegovy, it's $1,349. In contrast, the same supply of Ozempic costs as low as $83 in France and $87 in Australia. Historically, the introduction of generic drugs leads to substantial price reductions. It is not uncommon for generic versions to cost 30% to 80% less than their brand-name counterparts. With multiple competitors, prices can fall by as much as 85%. In China, at least 15 companies are already developing generic versions of semaglutide, with some in the final stages of clinical trials, positioning them for a potential market entry soon after the patent expires there. The U.S. market, however, will have to wait. Novo Nordisk has actively defended its patent portfolio for semaglutide, which includes patents on the drug's formulation and delivery methods, extending its market exclusivity. This has led to legal challenges and settlements with generic manufacturers. In October 2024, Novo Nordisk reached agreements with several major generic drug makers, likely defining the timeline for their eventual entry into the U.S. market. Therefore, while the announcement of a generic semaglutide is significant, its immediate impact will be felt outside the United States, offering a preview of the increased access and cost savings that may eventually arrive for American consumers.